Ex vivo expansion of satellite cells and directed differentiation of pluripotent cells to mature skeletal muscle have proved difficult challenges for regenerative biology. Using a zebrafish embryo culture system with reporters of early and late skeletal muscle differentiation, we examined the influence of 2,400 chemicals on myogenesis and identified six that expanded muscle progenitors, including three GSK3b inhibitors, two calpain inhibitors, and one adenylyl cyclase activator, forskolin. Forskolin also enhanced proliferation of mouse satellite cells in culture and maintained their ability to engraft muscle in vivo. A combination of bFGF, forskolin, and the GSK3b inhibitor BIO induced skeletal muscle differentiation in human induced pluripotent stem cells (iPSCs) and produced engraftable myogenic progenitors that contributed to muscle repair in vivo. In summary, these studies reveal functionally conserved pathways regulating myogenesis across species and identify chemical compounds that expand mouse satellite cells and differentiate human iPSCs into engraftable muscle.
INTRODUCTION
Skeletal muscle is a highly specialized tissue composed of nondividing, multinucleated muscle fibers that contract to generate force. Skeletal muscle is formed during embryogenesis in a region of the embryo known as the myotome. In addition to generating differentiated muscle fibers, embryonic progenitor cells also give rise to specialized muscle-forming stem cells, known as satellite cells (Gros et al., 2005; Seale et al., 2000) . Injury-induced satellite cell proliferation both replenishes the satellite cell pool and produces differentiated myoblasts, which fuse with existing myofibers and one another to regenerate muscle tissue.
Satellite cells are defined anatomically by their localization beneath the basal lamina of muscle fibers (Mauro, 1961) and molecularly by their expression of the paired-box transcription factor Pax7 (Seale et al., 2000) . Transplantation-based studies in animal models have demonstrated the utility of engrafted satellite cells for regenerating diseased muscle (Cerletti et al., 2008; Fukada et al., 2004; Kuang et al., 2007; Montarras et al., 2005; Sacco et al., 2008; Sherwood et al., 2004; Tanaka et al., 2009) , and analyses of mouse and human muscles indicate that their loss during aging contributes to age-associated muscle weakness (Brack et al., 2005; Cerletti et al., 2012; Chakkalakal et al., 2012; Shefer et al., 2010) . Thus, muscle satellite cells are promising targets for cell therapies, but the realization of this promise has been hindered by the paucity of satellite cells that can be isolated or expanded from adult muscle tissue.
In contrast to satellite cells, embryonic stem cells (ESCs) and, more recently, induced pluripotent stem cells (iPSCs), can expand indefinitely in culture. Although some success has been achieved in directing the myogenic differentiation of ESCs/IPSCs through genetic manipulation, selective culture, and cell sorting approaches (Awaya et al., 2012; Barberi et al., 2007; Darabi et al., 2008; Mizuno et al., 2010; Zheng et al., 2006) , the generation of well-differentiated muscle cells from human or murine pluripotent cells has proved challenging. In this study, we took a cross-systems approach to identify conserved molecular pathways that regulate muscle specification and satellite cell expansion in three vertebrate systems. Capitalizing on chemical genetics approaches in zebrafish, we performed a high-throughput image-based screen using zebrafish blastomere cells and identified 28 chemicals that perturb muscle development and 6 that promote myogenesis. We tested the muscle-promoting compounds against mouse satellite cells and human iPSCs to identify conserved activities. Forskolin, an adenylyl cyclase activator, significantly increased satellite cell proliferation in culture, expanding the capacity of these cells to regenerate dystrophic muscle upon transplantation. In addition, combination of bFGF, the GSK3b inhibitor BIO, and forskolin drove skeletal muscle specification of human iPSCs, including spontaneous differentiation to mature myofibers and the production of myogenic progenitors that contributed to muscle fibers and satellite cells when transplanted into immunecompromised mice. Our studies thus elucidate a combination of chemicals that promotes muscle development in fish, mouse, and human cells and establish a system to generate and expand mammalian muscle stem cells for functional studies of muscle development and therapeutics for musculoskeletal diseases.
RESULTS

A Zebrafish Embryo Culture System to Examine Skeletal Muscle Development
Myogenic commitment is signified by expression of myoD and myf5 (Weinberg et al., 1996) , which are functionally redundant and exhibit overlapping expression in the earliest myogenic precursors (Hinits et al., 2009) . Terminal differentiation of these progenitors produces cells expressing genes encoding muscle-specific structural proteins like myosin light polypeptide 2 (mylz2) (Ju et al., 2003) . To label different developmental states of muscle cells in zebrafish embryos, we generated a myf5-GFP;mylz2-mCherry double transgenic zebrafish line. At the 11-somite stage, myf5-GFP expression was restricted to the newly formed somite, and no mylz2-mCherry expression was detected ( Figure 1A ). Expression of mylz2-mCherry was first detected at 30 hr postfertilization (hpf) in the anterior somites and later spread to the posterior somites ( Figure 1A ). These data indicate that expression of myf5-GFP and mylz2-mCherry recapitulates the expression patterns of their corresponding endogenous genes (Thisse et al., 2001 ) and thus can be used to track myogenic specification from early embryonic progenitors.
To test whether zebrafish blastomere cells could form muscle in vitro, we disassociated myf5-GFP;mylz2-mCherry embryos at the oblong stage and plated them on gelatin-coated dishes. 1%-10% of cells cultured in zebrafish ESC (zESC) medium (Fan and Collodi, 2006) became GFP positive, indicating upregulation of myf5 expression. Among the GFP-positive cells, 1%-5% were also mCherry (mylz2) positive, suggesting that myogenic specification and differentiation had occurred ( Figure 1B) .
Loss of FGF signaling in fgf24 and fgf8 double-deficient zebrafish essentially blocks embryonic muscle development (Draper Figure S1 . et al., 2003) , and FGF signals directly activate myoD expression in Xenopus (Fisher et al., 2002) . Based on these data, we added bFGF to the embryo cultures. The majority of bFGF-treated cells became GFP and mCherry double positive, indicating a potent muscle-promoting effect (Figures 1B and S1A available online). Other myogenic genes, including myoD, mrf4, pax7, and myog, were also induced by blastomere cells cultured with bFGF ( Figure 1C ). Compared to the GFP/mCherry double-negative population, both the myf5-GFP + ;mylz2-mCherryÀ and the double-positive population isolated by FACS showed enriched myogenic gene expression and lower expression of blood (embryonic globin) and liver (ifabp) genes. Double-positive cells expressed higher levels of myoD and mylz2 than myf5-GFP + ;
mylz2-mCherryÀ cells, suggesting that, similar to the in vivo situation ( Figure 1A ), myf5-GFP and mylz2-mCherry label stagespecific myogenic populations in these in vitro cultures ( Figure 1D ). To validate this in vitro myogenesis system, we determined whether genes required for muscle development in vivo were also required in culture. Zebrafish embryos injected with myf5 and myoD double morpholinos are immobile, presumably due to defective muscle development (Schnapp et al., 2009 ). Expression of myogenic regulatory factors (mrfs), like myogenin and mrf4, and genes encoding structural proteins, like myosin heavy chain (mhc) and mylz2, are absent in the double morphant (Schnapp et al., 2009) . Consistent with these data, embryos injected with double morpholinos lacked myf5-GFP and mylz2-mCherry expression at 30 hpf ( Figure S1B ). Cultured blastomere cells from the double morphant also showed dramatically decreased expression of myf5-GFP and mylz2-mCherry ( Figure S1C ).
A Chemical Genetic Screen Identifies Modifiers of Skeletal Muscle Development
To enable higher throughput analysis of myogenesis modifiers, the embryo culture system was adapted to a semiautomated screening platform. myf5-GFP;mylz2-mCherry embryos were disassociated at the oblong stage, and the resulting individual blastomere cells were aliquoted into four 384-well plates with preadded chemicals. Culture medium was supplemented with bFGF to promote muscle development. After 1 day, the cells were automatically imaged (Figure 2A ).
We screened 2,400 chemicals from a bioactive drug library (Table S3 ) and identified 28 that perturbed the GFP or mCherry signals with undetectable toxicity. Based on changes in GFP (Myf5) and mCherry (Mylz2) signals, these 28 hits could be divided into three categories. Category I compounds produced cultures with only myf5-GFP-positive cells, a phenotype likely caused by blocking differentiation of muscle progenitors into mature muscle cells ( Figure 2B and Table S1 ). Ten chemicals, including inhibitors of the p38 pathway, previously shown to be required for muscle formation (Cuenda and Cohen, 1999; Wu et al., 2000; Zetser et al., 1999) , were included in category I. Category II included 17 chemicals that reduced the number of cells expressing either fluorescent color, likely because these chemicals block commitment of mesoderm progenitors to the muscle progenitor fate ( Figure 2B and Table S2 ). Category III held only one compound (SB415286, a GSK3b inhibitor), which increased expression of both markers, presumably by accelerating muscle development ( Figure 2B ).
To test whether these chemicals modulate myogenesis in vivo, we treated zebrafish embryos with each of the category II chemicals and evaluated the effect on myoD expression at the 6-somite stage. Among the 17 compounds tested, 11 caused decreased myoD expression in vivo, 2 induced nonspecific toxicity, and 4 produced no apparent effect ( Figure S2A and Table S2). 65% of the hits identified in our initial in vitro screen also perturbed muscle development in vivo, suggesting that this screening system can reveal in vivo muscle biology. bFGF induces muscle development by activating the FGF receptor tyrosine kinase (RTK). We identified three RTK inhibitors that block the muscle-promoting effect of bFGF ( Figure S2B ). double-transgenic embryos were collected and dissociated at the oblong stage. Resulting blastomere cells were aliquotted into four 384-well plates with preadded chemicals. After 2 days, the 384-well plates were imaged and analyzed using a Celigo cytometer. (B) Sample images from the modifier screen. Hits could be grouped into three categories. Category I has only myf5-GFP expression. Category II has a decreased amount of both fluorescent colors. Category III has increased expression of both. Scale bars represent 250 mm. (C) Hits from the enhancer screen. Six chemicals that increase the GFP and mCherry signals were identified. Scale bars represent 250 mM. See also Figure S2 and Tables S1 and S2. bFGF activates several intracellular pathways, including those involving MEK/ERK and phosphoinositide-3-kinase (PI3K)-AKT ( Figure S2C ). No MEK/ERK inhibitor was found to inhibit muscle development ( Figure S2B ). In contrast, the PI3K inhibitor LY-294002 completely blocked the muscle-promoting effect of bFGF ( Figure S2B ). Another PI3K inhibitor, wortmannin, had a similar effect ( Figure S2B ). Treatment with rapamycin, an mTOR inhibitor, blocked myogenesis induced by bFGF (Figure S2B ). These results suggest that bFGF promotes myogenesis through the PI3K-mTOR-rather than MEK/ERK-signaling pathway, although full mechanistic understanding of bFGF's promyogenic effect in this system awaits more detailed analyses.
A Sensitized Chemical Genetic Screen Identifies Enhancers of Skeletal Muscle Development
The strong muscle-promoting effect of bFGF made it difficult to identify enhancers of myogenesis in our original system. To sensitize the system for enhancers of muscle development, we repeated the screen in the absence of bFGF. In this sensitized screen, 6 chemicals out of 2,400 were identified to increase the GFP and mCherry signals ( Figures 2C and S2D ). These hits included three GSK3b inhibitors, two calpain inhibitors, and one cAMP activator forskolin.
None of the six chemicals increased myoD expression when applied to wild-type embryos, presumably due to a masking effect of the endogenous muscle program (data not shown). To evaluate the interaction of these chemicals with the FGF pathway, we injected embryos with morpholinos targeting fgf8 and fgf24 and assessed the ability of each chemical to rescue muscle development of fgf8;fgf24 double morphants, which displayed defective myogenesis as previously reported (Draper et al., 2003) . Of the six compounds tested, only forskolin rescued the myogenesis defect, indicating a unique activity of forskolin compared to the other compounds ( Figure S2E ).
Forskolin Treatment Elevates cAMP Levels and Expands Mouse Satellite Cells In Vitro
We hypothesized that chemical hits enhancing skeletal muscle development in zebrafish blastomeres might likewise promote muscle precursor cell formation and/or expansion in other species. We exposed satellite cells isolated by fluorescence-activated cell sorting (FACS) (Cerletti et al., 2008; Sherwood et al., 2004 ) from adult mouse skeletal muscle to these compounds. Satellite cells were cultured in the presence of different concentrations of each myogenesis-promoting chemical. Of the six chemicals tested, only forskolin triggered dose-dependent expansion of satellite cell cultures (data not shown). The number of cells in these cultures was increased by forskolin both in the presence and absence of bFGF ( Figure 3A ). Forskolin treatment also increased cell number in satellite cell cultures seeded from mdx mice, a model of Duchenne muscular dystrophy (DMD) (Sicinski et al., 1989) (Figures 3B and S3A ). The expanded forskolin-treated cells maintained expression of Pax7 and showed upregulation of MyoD, a marker profile consistent with activated satellite cells ( Figure S3B ).
To evaluate the mechanism by which forskolin drives increased cell number in satellite cell cultures, we assayed cyclic AMP (cAMP) production (Metzger and Lindner, 1981; Seamon et al., 1981) and found that forskolin treatment increased cAMP levels in mouse satellite cell cultures ( Figure 3C ). We also performed cell survival and proliferation assays in forskolin-treated cultures. Satellite cells were plated at one cell per well in 96-well plates and treated with forskolin or DMSO. After 6 days, we quantified the number of wells containing any number of myogenic cells (a measure of cell survival; Cerletti et al., 2012) and the number of cells in those wells (a measure of cell proliferation) ( Figure 3D ). The frequency of myogenic colony formation did not differ between forskolin-and DMSO-treated cells (Figure 3E) , suggesting that forskolin treatment does not affect cell survival. Consistent with our earlier observations ( Figure 3A ), myogenic colonies formed in the presence of forskolin contained more cells than DMSO-treated colonies ( Figure 3F ). Forskolintreated satellite cells were not immortalized, however, and maintained proliferative capacity in culture for approximately the same length of time as DMSO-treated cells (data not shown).
To test whether the increase in cell proliferation was caused by an inhibitory effect of forskolin on satellite cell differentiation, we expanded cultured satellite cells and induced them to differentiate in the presence or absence of forskolin. The percentage of nuclei in myotubes in each culture was quantified as a measure of myogenic differentiation ( Figure 4A ) and was not different between the forskolin and DMSO-treated groups (Figures 4B and 4C) . Satellite cells that were exposed to forskolin during growth and then induced to differentiate after removal of the compound ( Figure 4D ) also formed myotubes with the same efficiency as control-treated cells (Figures 4E and 4F) . Treatment with forskolin during both the proliferative and differentiation phases of culture also did not affect differentiation ( Figures  S4D-S4F ). Thus, forskolin-treated satellite cells exhibit unperturbed differentiation in vitro regardless of the timing of compound exposure. Unlike the synergistic effect of bFGF and forskolin for satellite cell expansion ( Figure 3A) , however, addition of bFGF during differentiation slightly reduced the number of nuclei incorporated into myotubes ( Figures S4A-S4C ), suggesting an inhibitory effect of bFGF on myogenic differentiation in the presence of forskolin ( Figures S4A-S4C ).
Forskolin-Treated Cells Retain Phenotypic Characteristics of Satellite Cells and Engraft into Dystrophic Skeletal Muscle In Vivo
Muscle satellite cells are highly enriched within the subset of myofiber-associated cells that coexpresses Cxcr4 and b1-Integrin (Sherwood et al., 2004) , and myogenic cells lacking CXCR4 and b1 integrin fail to engraft into mdx muscle (Cerletti et al., 2008) . High levels of Cxcr4 expression also predict high levels of Pax7 expression, which identifies a subset of serially transplantable satellite cells with muscle-stem-cell-like properties (Rocheteau et al., 2012) . Freshly isolated satellite cells are 100% positive for CXCR4 and b-1 integrin expression, and flow cytometric analysis revealed that 78.9% ± 1.52% of forskolin-expanded cells maintained coexpression of both these markers after 5 days in culture ( Figures 5A and 5B) . Thus, most satellite cells cultured in forskolin retain phenotypic characteristics of freshly isolated, engraftable muscle stem cells.
To assess directly the engraftment potential of cultured forskolin-treated satellite cells, we isolated cells from b-actin-GFP transgenic mice (Wright et al., 2001 ) using GFP as a marker for cell tracking in transplantation experiments. 6,000 GFP-expressing satellite cells were cultured for 5 days with forskolin, and the resulting cells were transplanted into the preinjured muscles of mdx mice ( Figure 5C ). Recipient muscles were harvested 3-4 weeks after transplant and analyzed for the presence of donor-engrafted, GFP-expressing myofibers. Consistent with the ability of forskolin to expand a primitive and engraftable myogenic cell population, the number of GFP + fibers was higher in animals receiving forskolin-expanded cells as compared to those receiving the original number of freshly isolated satellite cells or those receiving expanded DMSO-treated cells (Figures 5E and 5G) . In contrast, the number of engrafted fibers did not differ significantly when recipients were transplanted with equal numbers of cultured DMSO or forskolin-treated cells (Figures 5F and 5H) . Thus, exposure to forskolin expands mouse satellite cells in culture while maintaining their engraftment potential. This effect provides more cells for transplantation ( Figure 5D ) and a greater yield of engrafted fibers in vivo if the same number of satellite cells is first expanded with forskolin in vitro, compared to control. Myofibers engrafted by forskolin-treated cells stained for Dystrophin, which normally is absent in mdx muscle ( Figure S3C ), indicating that forskolin-expanded donor cells maintain in vivo myogenic activity and can produce functional myoblasts that incorporate into myofibers and produce muscle-specific proteins.
A Combination of bFGF, BIO, and Forskolin Activates the Skeletal Muscle Program in iPSCs
It is currently difficult to differentiate human iPSCs or ESCs to the skeletal muscle lineage, with the greatest successes involving ectopic introduction and overexpression of muscle-specific transcription factor genes (Darabi et al., 2012; Tedesco et al., 2012) . Strategies to drive myogenic differentiation of pluripotent cells in the absence of ectopic transcription factor expression have typically required multistep culture and cell-sorting protocols that are very time and labor intensive (Awaya et al., 2012; Barberi et al., 2007) .
We tested the effects of muscle-promoting compounds on the differentiation of three different lines of iPSCs (00409, 05400, and BJ) derived from healthy human donor skin fibroblasts by retroviral transduction with the reprogramming factors Oct4, Klf4, Sox2, and c-Myc (Figures S5A-S5D ). Embryoid bodies (EB) from BJ, 00409, or 05400 iPSCs were exposed for 7 days to a serum-free differentiation medium containing bFGF (10 ng/ml), BIO (0.5 mM), and forskolin (20 mM) (medium added at days 1, 3, and 5). We used BIO rather than the GSK3b inhibitors found in the screen because, of the several GSK3b antagonists tested, BIO displayed the lowest toxicity on monolayer iPSCs and differentiating EBs ( Figures S5E and S5F) . After 7 days, we measured the expression of a panel of markers specific for ectoderm, endoderm, or mesoderm to assess differentiation outcomes. The mesodermal markers GATA2, PAX7, MYF5, and MYOD1 genes were significantly upregulated after 2, 4, and 7 days of differentiation, compared to the corresponding undifferentiated iPSCs ( Figures 6A, S6A , and S6B). In contrast, ectodermal and endodermal genes were not significantly altered. Immunostaining experiments confirmed these results and showed that muscle-specific proteins (PAX7, MYF5, and MYOD1) were present in the nuclei of EB cells differentiating under these conditions ( Figure S6F ). These data suggest that this three-chemical mixture specifically favors the mesodermal lineage and promotes myogenic specification. Two-way combinations, such as bFGF + BIO or bFGF + forskolin, yielded significantly less potent myogenic induction as compared to the bFGF/BIO/forskolin ''triple cocktail'' ( Figures S5G and  S5H) . To determine whether iPSC-derived cells undergo terminal skeletal muscle differentiation with bFGF/BIO/forskolin, EBs were plated on matrigel-coated dishes for further differentiation. Gene expression analysis of these cultures revealed that PAX7, MYOD1, and MYF5 remained increased after 36 days of culture. Expression of Myogenin and MyHC, two markers of late myogenic differentiation, increased after 20 days, and this increase became more pronounced after 36 days ( Figure 6B ). At day 36, we observed many multinucleated myotubes, which stained for Desmin and Myogenin ( Figure 6C ). Although iPSCs can differentiate spontaneously to cardiac cells, gene expression analysis revealed no increase in cardiac markers (NKX2.5 and GATA2) after 36 days of differentiation, and no spontaneously beating cells were found in the treated cultures. In contrast, beating cells were observed in the untreated cell lines after 12-14 days (data not shown). Thus, the three compounds together induced a skeletal myogenic-rather than cardiogenicprogram. We also confirmed the skeletal muscle fate of iPSC-derived cells cultured in bFGF/BIO/forskolin by electron microscopy (EM) and immunogold staining with antihuman skeletal muscle Myosin and heavy and light chain antibodies (sk-Myosin-HLChains). EM analysis of BJ iPSC-derived cells harvested from culture after 36 days revealed the presence of distinct sarcomere structures, which stained positively for sk-Myosin-HL-Chains ( Figures 6D and 6E) . Similar results were obtained in 00409 and 05400 iPSCs ( Figures S6C-S6E ).
iPSCs-Derived Muscle Progenitors Can Engraft into Skeletal Muscle In Vivo
To determine whether myogenic specification using bFGF/BIO/ forskolin could generate or expand engraftable muscle progenitors from human pluripotent cells, we assessed the ability of cells derived from human iPSCs to support muscle regeneration in vivo. BJ, 05400, or 00409 iPSCs were differentiated by treatment with bFGF/BIO/forskolin and transplanted into immunodeficient mice after 14 days of differentiation. This time point was chosen because expression of the satellite-cell-specific transcription factor PAX7 peaks at 14 days ( Figure 6B ). iPSC-derived cells were transplanted directly into the limb muscle of NOD/ SCID/IL2Rg À/À (NSG) mice that had been preinjured by cardiotoxin injection 24 hr before transplantation. The contralateral muscles of recipient mice were injured but injected with only PBS. One month after transplantation, muscles were harvested No staining is observed in PBS-injected mice or when 00409 fibroblast cells were transplanted. Because the area of human cell engraftment could not be specifically distinguished on H&E stained sections, which must be processed differently from sections for immunostaining, the H&E images shown do not represent the same muscle region as that shown in immunofluorescence images. Scale bars represent 100 mm, n = 3 per sample. See also Figure S7 .
and analyzed for engraftment by immunostaining with human muscle-specific d-Sarcoglycan antibody. PBS-injected muscle showed no detectable staining for human d-Sarcoglycan (Figure 7) . Human d-Sarcoglycan + fibers were also absent when 00409-derived fibroblast cells were transplanted (Figure 7) . By contrast, transplantation of myogenic progenitors derived from any of the three iPSC lines (BJ, 05400, or 00409) yielded significant engraftment of cells that showed clear reactivity for human d-Sarcoglycan (Figure 7 ). To test whether engrafted cells also contributed to the satellite cell compartment in recipient muscles, we performed immunostaining using human-specific histone H2A and Pax7 antibodies. Pax7 and human H2A staining colocalized in a subset of nuclei in the engrafted muscle, indicating that the transplanted iPSC-derived cells also populated the satellite cell compartment (Figures S7A and S7B) . No human H2A staining was observed in PBS-injected mice. Thus, iPSC-derived progenitor cells generated by treatment with bFGF/BIO/forskolin maintain myogenic commitment and support regenerative myogenesis after in vivo transplantation.
DISCUSSION
In this study, we took advantage of chemical genetic approaches available in zebrafish to reveal conserved mechanisms controlling the specification and expansion of myogenic progenitor cells. Although prior studies have employed chemical genetics in whole zebrafish embryos to interrogate development and disease, this approach requires time-consuming manipulation of embryos and whole-mount in situ hybridization. Some laboratories have screened embryos using high-speed pipetting and imaging, but the three-dimensional structure of the embryo makes this approach rather difficult. The culture-based screening system reported here takes one-sixth the time and uses one-tenth the embryos. Such throughput enables screening of larger chemical libraries with greater speed than chemical screening on mammalian cell lines. Transgenic zebrafish with fluorescent reporters known to label a particular cell type in vivo can be used, and images can be automatically captured and stored such that the cells need not be fixed or scored immediately. Recently, a zebrafish explant system with some similarities to our embryo culture system identified compounds that could expand angiogenic progenitors (Huang et al., 2012) . Our system is distinct in that it enables the combination of reporters of different colors to simultaneously interrogate multiple developmental states or lineages. Nevertheless, both systems utilize zebrafish embryonic cells to examine signaling events that participate in organ development in vitro.
A noteworthy attribute of the zebrafish embryo culture system is its ability to identify pathways that influence tissue specification and progenitor cell expansion across species. Chemicals found in our zebrafish system expand postnatal muscle satellite cells from mice and specify myogenic differentiation from human pluripotent cells, thus helping to address two of the more vexing challenges in the production of mammalian muscle precursors for experimental applications and, ultimately, cell therapy. One major obstacle in using purified skeletal muscle satellite cells for therapy is their very low frequency in adult tissue. High numbers of engraftable cells are required for functional recovery of skeletal muscles throughout the body in genetic muscle disorders, and efforts to expand purified satellite cells in culture while maintaining their engraftment potential have been largely unsuccessful (Montarras et al., 2005) . We show that mouse muscle progenitors treated with the adenylyl cyclase activator forskolin exhibit enhanced proliferation in culture. These data are consistent with a previous report showing that activation of cAMP signaling in transgenic mice expressing an activated form of cAMP response element binding protein (CREB) increases the in vitro proliferation of primary myoblasts (Stewart et al., 2011) and contrast with the cell-cycle inhibitory effects of this chemical in some other systems (e.g., human T cells [Rodriguez et al., 2013] and thyroid cancer cell lines [Yano et al., 2007] ). Forskolin does not inhibit satellite cell differentiation in vitro, and forskolintreated muscle progenitors differentiate normally after removal of the compound or in its continued presence. Satellite cells cultured with forskolin retain most phenotypic characteristics of freshly isolated satellite cells. Forskolin may mimic activation of a natural G-protein-coupled receptor involved in the genesis or maintenance of muscle progenitors. When transplanted into preinjured mdx muscle, forskolin-expanded satellite cells engrafted to generate Dystrophin-expressing myofibers. Forskolin treatment also enhanced proliferation of satellite cells from dystrophic mdx mice, which exhibited defective ex vivo expansion under control conditions. Forskolin thus may be useful to promote ex vivo expansion of human dystrophic satellite cells for autologous therapy or to improve the efficiency of cell replacement strategies for muscle disorders.
The capacity of forskolin to expand functional satellite cells may explain the enhanced myogenesis observed in zebrafish blastomeres and human iPSCs upon forskolin exposure. During culture, some pluripotent cells likely differentiate to form muscle progenitors, and forskolin may act to increase the proliferation of these myogenic cells by activating cAMP signaling, thereby enriching muscle-forming capacity. Given prior difficulties in obtaining robust skeletal muscle differentiation from pluripotent cells, most studies have relied on transgenic modification (Darabi et al., 2012; Tedesco et al., 2012) . By applying insights obtained from our zebrafish embryo culture screen, we identified a chemical cocktail that successfully enabled myogenic differentiation of iPSCs into mature myofibers in vitro and in vivo in the absence of genomic modification or transcription factor overexpression. A screen to find such chemical inducers of muscle development using iPSCs would have been highly reagent and labor intensive, particularly as myogenic differentiation in the human system requires $36 days. In contrast, the zebrafish protocol takes only 1-2 days, enabling the completion of a smallscale screen in about 1 week.
One remarkable aspect of the myogenic protocol defined here is the selectivity with which the skeletal muscle fate is specified during culture. Simultaneous inhibition of GSK3b and activation of cAMP and bFGF pathways during EB formation are sufficient to specifically promote commitment to skeletal muscle differentiation, and our marker analysis indicates that alternative fates, including cardiac and neural lineages, are relatively rare in cultures exposed to the triple cocktail. Although we observed modest variability in gene expression changes among the three different iPSC lines used, likely reflecting differences in the genetic background of the three different human donors, all three lines exhibited potent muscle differentiation in response to the bFGH/BIO/forskolin cocktail. Prior studies indicate that cAMP signaling is increased at discrete times during embryonic muscle differentiation and promotes regeneration and metabolic adaptation in satellite cells (Carlsen, 1975; Chen et al., 2005; Le Peuch et al., 1979; Zalin and Montague, 1975) . Myogenesis of muscle stem cells can also be induced by Wnt activation (Brack et al., 2008; Polesskaya et al., 2003) , and bFGF-mediated activation of PI3K-AKT pathway has been reported as a potent mediator of muscle differentiation (Stitt et al., 2004) . These results, together with the ability to achieve myogenic specification of iPSCs using a simple cocktail of defined chemicals, raise the possibility that iPSC-derived myogenic cells could one day be applied to regenerative cell therapy for the treatment of musculoskeletal diseases. The findings reported here should prove highly beneficial to understanding normal myogenesis and for in vitro studies of muscle and metabolic disease in a variety of experimental settings.
EXPERIMENTAL PROCEDURES
Culture of Disassociated Blastomere Cells Disassociated blastomere cells were grown in zESC medium composed of 70% LDF medium and 30% RTS34st-conditioned medium. LDF medium contains 50% Leibowitz's L-15 (Invitrogen), 35% DMEM (Invitrogen), and 15% Ham's F-12 (Invitrogen), supplemented with 0.18 g/l sodium bicarbonate, 15 mM HEPES (Invitrogen),1% L-Glutamine (Invitrogen), 10 mg/ml ciprofloxacin (Sigma-Aldrich), 100 mg/ml piperacillin (Sigma-Aldrich), 10 mg/ml amphotericin B (Sigma-Aldrich), 10 nM sodium selenite (Sigma-Aldrich), 1% N2 (Invitrogen), and 2% B27 (Invitrogen). RTS34st conditioned medium was prepared by incubating fresh medium (Leibowitz's L-15 plus 15% FBS) on a confluent culture of RTS34st cells for 3 days.
High-Throughput Screen
Four 384-well plates were coated with 0.1% gelatin. Chemicals from the CHB library (see Table S3 ) were diluted 150 times with zESC medium containing 1 ng/ml bFGF and were aliquoted 30 ml per well. Males and females of the myf5-GFP;mylz2-mCherry transgenic line were set up overnight and kept separated until morning when they were mixed for mating. Approximately 800 oblong-stage embryos were washed three times with E3 embryo water and treated with pronase to remove chorions. Dechorionated embryos were washed with E3 embryo water three times and collected into a 50 ml falcon tube with 25 ml zESC medium containing 1 ng/ml bFGF. Embryos were disassociated by shaking $20 times and were filtered through a 70 mm nylon mesh filter. Resulting single cells were diluted to 60 ml with zESC medium containing 1 ng/ml bFGF and aliquoted 30 ml per well into the four 384-well plates with preadded chemicals. Cells were cultured in a 28 C incubator without CO 2 . Cells were imaged by a Celigo cytometer (Cyntellect). Images were analyzed by the built-in software and confirmed by eye.
Satellite Cell Isolation and Culture
Satellite cell isolation was performed as previously described (Cerletti et al., 2008; Sherwood et al., 2004) . For in vitro expansion experiments, CD45
-integrin + cells were seeded on collagen/laminincoated plates in F10 (GIBCO) containing 20% horse serum (Atlanta Biologics), 1% penicillin-streptomycin (Invitrogen), and 1% glutamax (Invitrogen). Where indicated, 5 ng/ml bFGF (Sigma) was added to the medium daily. 50 mM forskolin (Santa Cruz) or 0.1% DMSO was added to the wells 24 hr after plating, and the medium was changed with fresh medium containing DMSO or forskolin 48 hr after plating with treatment continued for 36 more hours, after which the medium was changed for fresh medium without compound. Cells were counted or used for transplant after 5 days in culture. For myogenic colonyforming assays, cells were fixed and counted after 6 days in culture. For differentiation, cells were cultured 5 days with or without compound, and on day 5, equal numbers (8,000) of cells were replated in each well of a 96-well plate in growth medium. Medium was changed after 4 hr to DMEM (GIBCO) containing 2% horse serum (Atlanta Biologics), 1% penicillin-streptomycin (Invitrogen), with or without 50 mM Forskolin or 0.1% DMSO. Cells were fixed after 60 or 72 hr in differentiation medium.
Tissue Injury and Mouse Satellite Cell Transplantation 25 ml (0.03 mg/ml) of Naja mossambica mossambica cardiotoxin (Sigma) was injected in the tibialis anterior (TA) muscle of anesthetized mdx mice 1 day before cell transplantation. The next day, 6,000 freshly isolated double-sorted GFP + satellite cells or the total number of cells expanded from 6,000 SMPs after 5 days in culture were injected directly into these preinjured muscles in 20 ml PBS. For transplantation with equal numbers of cultured compound treated cells, 200,000 forskolin or 200,000 DMSO-treated cells were injected. The contralateral TA was injected with PBS only as a negative control. Transplanted muscles were harvested 3-4 weeks after transplant and analyzed by cryosectioning and microscopy.
Culture and Differentiation of Human iPSCs BJ-iPSCs (Maherali et al., 2008) were obtained from Chad Cowan (Harvard Stem Cell Institute). 05400 and 00409 iPSCs lines were generated from human adult skin fibroblasts by retroviral transduction of KLF4, SOX2, OCT4, and c-MYC reprogramming factors as in Takahashi et al. (2007) and Park et al. (2008) . Pluripotency of these lines was assessed by colony morphology; immunostaining for NANOG, OCT4, SSEA3-4, and Tra1-60; gene expression of NANOG, OCT4, SOX2, REX1, TERT, and DNm3b; and EB formation. Pluripotent iPSCs were maintained on matrigel-coated dishes (BD) in mTeSR1 medium (STEMCELL Technologies). iPSCs were differentiated to skeletal muscle by generating EBs in suspension culture for 7 days and then transferred to matrigel-coated plates for an additional 29 days. During suspension culture, the cells received differentiation medium STEMDiff Apel medium (STEMCELL technologies) supplemented with 10 ng/ml bFGF (Invitrogen), 0.5 mM BIO (Santa Cruz Biotechnologies), and 20 mM forskolin (Santa Cruz Biotechnologies). 2 to 3 days after plating EBs, the medium was switched to DMEM supplemented with 2% horse serum for the remaining differentiation.
Transplantation of iPSC-Derived Muscle Progenitors 5-to 6-week-old NSG mice from Jackson Laboratories (stock #002378) were preinjured by intramuscular injection of 0.03 mg/ml cardiotoxin 1 day prior to cell transplantation. After 24 hr, myogenic progenitors (1 3 10 5 cells/ 25 ml PBS) were injected into the left TA muscle, whereas the right leg of each mouse received the same amount of PBS as a negative control. One month later, mice were sacrificed, and muscles were harvested and frozen in iso-pentane cooled in liquid nitrogen. Serial cryosections were fixed with 4% PFA and stained with anti-d-Sarcoglycan (Leica), anti-Laminin (Abcam), anti-histone H2A (Santa Cruz), and anti-Pax7 (R&D) antibodies. We observed no tumor formation in mice followed for up to 45 days after transplant of iPSC-derived myogenic progenitors; it will be important to perform longer-term follow up to fully exclude tumorigenic potential in these cells.
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